to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10797257.str





chain nodes :
7 8 9 10 11 12 13
ring nodes :
1 2 3 4 5 6
chain bonds :
4-7 5-12 6-8 8-9 9-10 10-11 12-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 6-8 8-9 12-13
exact bonds :
5-12 9-10 10-11
isolated ring systems :
containing 1 :

G1:C,O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S

<09/07/2005> Habte

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 08:50:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     19 TO ITERATE

100.0% PROCESSED       19 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          119 TO      641
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 08:50:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    262 TO ITERATE

100.0% PROCESSED      262 ITERATIONS                               18 ANSWERS
SEARCH TIME: 00.00.01

L3            18 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             161.33     161.54

FILE 'CAPLUS' ENTERED AT 08:50:49 ON 07 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 7 Sep 2005  VOL 143 ISS 11
FILE LAST UPDATED: 6 Sep 2005  (20050906/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l3
L4             2 L3
```

=> d ibib abs hitstr tot

own work

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:817887 CAPLUS
DOCUMENT NUMBER: 141:314052
TITLE: Preparation of prostaglandin analogs as EP4 receptor agonists for the treatment of glaucoma
INVENTOR(S): Billot, Xavier; Colucci, John; Han, Yongxin; Wilson, Marie-Claire; Young, Robert N.
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004085430	A1	20041007	WO 2004-CA470	20040326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004198701	A1	20041007	US 2004-797257	20040310
WO 2004085431	A1	20041007	WO 2004-CA471	20040326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-457700P P 20030326
OTHER SOURCE(S): MARPAT 141:314052
GI

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I II

AB Prostaglandin analogs of formula I [Q = alkylene, alkylarylene, alkylcycloalkylene, etc.; X, Y = CH2, O, (substituted) NH, S; U = H, alkyl, absent; W = OH, oxo; R1 = hydroxyalkyl, cyanoalkyl, carboxy, heterocyclylalkyl, etc.; R2 = alkyl, aryl, heteroaryl, etc.; R3, R4 = H, halo, alkyl; R3R4 = alkylene, etc.; Z = triple bond, O, S, CH=CH, etc.; n = 0-4] are prepared as potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, and can be used in a formulation for the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compds. of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts. Thus, II was prepared in several steps from (R)-pipecolinic acid.

IT 768399-98-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of prostaglandin analogs as EP4 receptor agonists for the treatment of glaucoma)

RN 768399-98-0 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-, 1-methylethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 768399-99-1P 768400-11-9P 768400-14-2P

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

768400-16-4P 768400-18-6P 768400-21-1P
768400-26-6P 768400-29-9P 768400-32-4P
768400-35-7P 768400-37-9P 768400-40-4P
768400-43-7P 768400-46-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of prostaglandin analogs as EP4 receptor agonists for the treatment of glaucoma)

RN 768399-99-1 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-11-9 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-14-2 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]dihydro-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 768400-16-4 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, dihydro-4-[(3R)-3-hydroxy-4-phenylbutyl]-2-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 768400-18-6 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-, 1-methylethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-21-1 CAPLUS
CN 2H-1,3-Oxazin-2-one, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]tetrahydro-3-[6-(1H-tetrazol-5-yl)hexyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 768400-26-6 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[3-[(4R)-dihydro-4-[(1E,3S)-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-29-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 768400-37-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[3-[(4R)-dihydro-4-[(1E,3S)-3-hydroxy-4-phenyl-1-butenyl]-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-40-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 5-[3-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]propyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 768400-32-4 CAPLUS
CN 2H-1,3-Oxazin-2-one, 4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]tetrahydro-3-[3-[5-(1H-tetrazol-5-yl)-2-thienyl]propyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-35-7 CAPLUS
CN 2H-1,3-Oxazin-2-one, 4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]tetrahydro-3-[3-[5-(1H-tetrazol-5-yl)-2-thienyl]propyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 768400-43-7 CAPLUS
CN 5-Heptenoic acid, 7-[(4R)-4-[(1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-butenyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]-, (5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 768400-46-0 CAPLUS
CN 5-Heptenoic acid, 7-[(4S)-4-[(3R)-4,4-difluoro-3-hydroxy-4-phenylbutyl]dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl]-, (5E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 768400-09-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of prostaglandin analogs as EP4 receptor agonists for the treatment of glaucoma)
RN 768400-09-5 CAPLUS
CN 2H-1,3-Oxazine-3(4H)-heptanoic acid, 4-[(1E)-4,4-difluoro-3-oxo-4-phenyl-1-butenyl]dihydro-2-oxo-, 1-methylethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 128276-15-3 CAPLUS
CN 2H-1,3-Oxazin-2-one, 3-acetyl-4-dodecyltetrahydro- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1990:459177 CAPLUS
DOCUMENT NUMBER: 113:59177
TITLE: Preparation of oxazolidinone penetration enhancing compounds
INVENTOR(S): Rajadhyaksha, Vithal J.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9000407	A1	19900125	WO 1989-US2779	19890623
W: JP				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4960771	A	19901002	US 1988-218316	19880712
EP 378657	A1	19900725	EP 1989-908033	19890623
EP 378657	B1	19940202		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03500298	T2	19910124	JP 1989-507546	19890623
JP 2901297	B2	19990607		
AT 101046	E	19940215	AT 1989-908033	19890623
PRIORITY APPLN. INFO.:			US 1988-218316 A	19880712
			EP 1989-908033 A	19890623
			WO 1989-US2779 W	19890623

OTHER SOURCE(S): CASREACT 113:59177; MARPAT 113:59177
GI



I II

AB Title compds. I (R = H, C1-18 alkyl, cycloalkyl, aryl, aralkyl, alkoxy, etc.; X = O, R1N, R1 = H, alkyl, aralkyl, C1-18 acyl, cycloalkyl, etc.; Y = O, R2N, R2 = H, alkyl, aralkyl, cycloalkyl, C1-18 acyl, hydroxyalkyl, etc.; m = 2-4; n = 0-4, with several provisos) are prepared Me(CH2)9CHNH2CH2OH and ethylene carbonate were heated to .apprx.110° to give 4-decyloxazolidin-2-one (II). In a test using isosorbide dinitrate (0.07%) and 1.4% II, II showed superior permeation enhancing properties compared to control and a known permeation enhancer.

IT 128276-14-2 128276-15-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(penetration enhancer for topical pharmaceuticals)

RN 128276-14-2 CAPLUS
CN 2H-1,3-Oxazin-2-one, 4-dodecyltetrahydro-3-methyl- (9CI) (CA INDEX NAME)

KM

Day : Wednesday

Date: 9/7/2005
Time: 12:46:48

PALM INTRANET

Inventor Information for 10/797257

Inventor Name	City	State/Country
BILLOT, XAVIER	MONTREAL	CANADA
COLUCCI, JOHN	KIRKLAND	CANADA
HAN, YONGXIN	KIRKLAND	CANADA
WILSON, MARIE-CLAIRE	CARLSBAD SPRINGS	CANADA
YOUNG, ROBERT N.	SENNEVILLE	CANADA

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity Data | Foreign Data

Search Another: Application# [ ] Search **or Patent#** [ ] Search

PCT / [ ] / [ ] Search **or PG PUBS #** [ ] Search

Attorney Docket # [ ] Search

Bar Code # [ ] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	606	544/96, 544/97, 514/228.8	USPAT	OR	OFF	2005/09/07 13:14